CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
Hyundai Bioscience leads in the repurposing of Niclosamide
SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-reno...
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19
SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem
SEOUL, South Korea, Dec. 8, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) released a report onDecember 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activit...
Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatme...
'Curing Cancer without Surgery'
* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...
